Standardization of Somatic Variant Classifications in Solid and Haematological Tumours by a Two-Level Approach of Biological and Clinical Classes: An Initiative of the Belgian ComPerMed Expert Panel
暂无分享,去创建一个
Joni Van der Meulen | Guy Froyen | Marie Le Mercier | Els Lierman | Karl Vandepoele | Friedel Nollet | Elke Boone | Koen Jacobs | Suzan Lambin | Sara Vander Borght | Els Van Valckenborgh | Aline Antoniou | Aline Hébrant | A. Antoniou | K. Vandepoele | G. Froyen | E. Boone | E. Van Valckenborgh | M. Le Mercier | E. Lierman | S. Vander Borght | A. Hebrant | S. Lambin | F. Nollet | Joni Van der Meulen | K. Jacobs
[1] Trevor J Pugh,et al. Integration of Technical, Bioinformatic, and Variant Assessment Approaches in the Validation of a Targeted Next-Generation Sequencing Panel for Myeloid Malignancies. , 2017, Archives of pathology & laboratory medicine.
[2] Marilyn M. Li,et al. Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. , 2017, The Journal of molecular diagnostics : JMD.
[3] Bale,et al. Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.
[4] M. Esteller,et al. Epigenetic inactivation of tumour suppressor coding and non-coding genes in human cancer: an update , 2017, Open Biology.
[5] Heidi L Rehm,et al. Updated recommendation for the benign stand‐alone ACMG/AMP criterion , 2018, Human mutation.
[6] Shujiro Okuda,et al. Next generation sequencing‐based gene panel tests for the management of solid tumors , 2018, Cancer science.
[7] J. Cigudosa,et al. Spanish Guidelines for the use of targeted deep sequencing in myelodysplastic syndromes and chronic myelomonocytic leukaemia , 2019, British journal of haematology.
[8] Dmitriy Sonkin,et al. TP53 Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data , 2016, Human mutation.
[9] N. Socci,et al. Accelerating Discovery of Functional Mutant Alleles in Cancer. , 2018, Cancer discovery.
[10] F. Supek,et al. The rules and impact of nonsense-mediated mRNA decay in human cancers , 2016, Nature Genetics.
[11] Madhuri Hegde,et al. Reassessment of Genomic Sequence Variation to Harmonize Interpretation for Personalized Medicine. , 2016, American journal of human genetics.
[12] Angie Duy Vo,et al. Identifying fusion transcripts using next generation sequencing , 2016, Wiley interdisciplinary reviews. RNA.
[13] Jing Huang,et al. Non‐small cell lung cancer harboring a rare EGFR L747P mutation showing intrinsic resistance to both gefitinib and osimertinib (AZD9291): A case report , 2018, Thoracic cancer.
[14] C. von Kalle,et al. Precision oncology based on omics data: The NCT Heidelberg experience , 2017, International journal of cancer.
[15] K. Stamatopoulos,et al. ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia—update on methodological approaches and results interpretation , 2018, Leukemia.
[16] Bijal A. Parikh,et al. Optimization of Population Frequency Cut-offs for Filtering Common Germline Polymorphisms from Tumor-Only Next-Generation Sequencing Data. , 2019, The Journal of molecular diagnostics : JMD.
[17] Raymond Dalgleish,et al. HGVS Recommendations for the Description of Sequence Variants: 2016 Update , 2016, Human mutation.
[18] Christopher J. Richardson,et al. Mutational patterns in oncogenes and tumour suppressors. , 2016, Biochemical Society transactions.
[19] Keith Nykamp,et al. Sherloc: a comprehensive refinement of the ACMG–AMP variant classification criteria , 2017, Genetics in Medicine.
[20] S. van Vooren,et al. Somatic Tumor Variant Filtration Strategies to Optimize Tumor-Only Molecular Profiling Using Targeted Next-Generation Sequencing Panels. , 2019, The Journal of molecular diagnostics : JMD.
[21] Melanie Boerries,et al. Variant classification in precision oncology , 2019, International journal of cancer.
[22] C. Cole,et al. COSMIC (Catalogue of Somatic Mutations in Cancer) , 2014 .
[23] Weiwei Ning,et al. Exon 19 L747P mutation presented as a primary resistance to EGFR-TKI: a case report. , 2016, Journal of thoracic disease.
[24] Birgit Funke,et al. ClinGen Variant Curation Expert Panel experiences and standardized processes for disease and gene‐level specification of the ACMG/AMP guidelines for sequence variant interpretation , 2018, Human mutation.
[25] Suzanne Kamel-Reid,et al. A classification system for clinical relevance of somatic variants identified in molecular profiling of cancer , 2015, Genetics in Medicine.
[26] Yunyun Ni,et al. Houston Methodist Variant Viewer: An Application to Support Clinical Laboratory Interpretation of Next-generation Sequencing Data for Cancer , 2017, Journal of pathology informatics.
[27] R. Luthra,et al. Next-Generation Sequencing in Clinical Molecular Diagnostics of Cancer: Advantages and Challenges , 2015, Cancers.
[28] B. Ebert,et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. , 2015, Blood.
[29] Rodrigo Dienstmann,et al. Standardized decision support in next generation sequencing reports of somatic cancer variants , 2014, Molecular oncology.
[30] Vijai Joseph,et al. Conflicting Interpretation of Genetic Variants and Cancer Risk by Commercial Laboratories as Assessed by the Prospective Registry of Multiplex Testing , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] K. Kinzler,et al. Cancer Genome Landscapes , 2013, Science.
[32] N. Schultz,et al. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[33] Peter Horak,et al. Integrating next-generation sequencing into clinical oncology: strategies, promises and pitfalls , 2016, ESMO Open.
[34] Dennis C. Friedrich,et al. Whole-exome sequencing and clinical interpretation of formalin-fixed , paraffin-embedded tumor samples to guide precision cancer medicine , 2014 .
[35] Erdogan Taskesen,et al. Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity. , 2011, Blood.
[36] S. Puig,et al. Prevalence of pathogenic/likely pathogenic variants in the 24 cancer genes of the ACMG Secondary Findings v2.0 list in a large cancer cohort and ethnicity-matched controls , 2018, Genome Medicine.
[37] M. Chiarini,et al. CEBPA–double-mutated acute myeloid leukemia displays a unique phenotypic profile: a reliable screening method and insight into biological features , 2016, Haematologica.
[38] Linda Jo Bone Jeng,et al. An openly available online tool for implementing the ACMG/AMP standards and guidelines for the interpretation of sequence variants , 2016, Genetics in Medicine.
[39] Heather Mason-Suares,et al. The current state of clinical interpretation of sequence variants. , 2017, Current opinion in genetics & development.